Sign In
Buy ADAP
$0.0549
+0 (+0%)
At Close: Feb 20, 2026
Surface Oncology (SURF) Gets a Buy Rating from JonesTrading
04:32pm, Monday, 09'th Mar 2020
JonesTrading analyst Soumit Roy reiterated a Buy rating on Surface Oncology (SURF) today and set a price target of $12.00. The company's shares closed
Surface Oncology (SURF) Gets a Buy Rating from JonesTrading
04:32pm, Monday, 09'th Mar 2020
JonesTrading analyst Soumit Roy reiterated a Buy rating on Surface Oncology (SURF – Research Report) today and set a price
Zacks Investment Research Lowers Adaptimmune Therapeutics (NASDAQ:ADAP) to Hold
10:40am, Saturday, 07'th Mar 2020
Zacks Investment Research downgraded shares of Adaptimmune Therapeutics (NASDAQ:ADAP) from a buy rating to a hold rating in a report published on Tuesday morning, Zacks.com reports. According to Zacks
Cellectis SA (CLLS) Received its Third Buy in a Row
08:01pm, Thursday, 05'th Mar 2020
After William Blair and BTIG gave Cellectis SA (NASDAQ: CLLS) a Buy rating last month, the company received another Buy, this time from JonesTrading.
Cellectis SA (CLLS) Received its Third Buy in a Row
08:01pm, Thursday, 05'th Mar 2020
After William Blair and BTIG gave Cellectis SA (NASDAQ: CLLS) a Buy rating last month, the company received another Buy,
JonesTrading Sticks to Their Buy Rating for Infinity Pharma (INFI)
06:29pm, Wednesday, 04'th Mar 2020
JonesTrading analyst Soumit Roy reiterated a Buy rating on Infinity Pharma (INFI) today and set a price target of $3.50. The company's shares closed last
JonesTrading Sticks to Their Buy Rating for Infinity Pharma (INFI)
06:29pm, Wednesday, 04'th Mar 2020
JonesTrading analyst Soumit Roy reiterated a Buy rating on Infinity Pharma (INFI – Research Report) today and set a price
Sutura Therapeutics Appoints James Noble and Eduardo Bravo to Board of Directors
11:00pm, Monday, 02'nd Mar 2020Analyst Explains Why They Downgraded Their Rating on Forty Seven (FTSV)
03:07pm, Monday, 02'nd Mar 2020
Forty Seven (FTSV) received a Hold rating from JonesTrading analyst Soumit Roy today. The company's shares closed last Monday at $93.86, close to its
